Durvalumab
Therapeutic Durvalumab antibody from the original Imfinzi® commercial drug.
Reference Standard as Aliquots
Product Batch
| Expiry Date
| Brand & Origin
| Amount per Aliquot
| Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2021.10 |
Imfinzi® DE |
2 mg |
aliquot |
Order on demand:
|
218,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Imfinzi® / Durvalumab Reference Product
| Drug name | Imfinzi® |
| INN | Durvalumab |
| API type | Durvalumab is a human monoclonal IgG1κ antibody |
| Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies |
| ATC code | L01XC28 |
| Target of antibody | PD-L1 Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, RGD1566211 |
| General function | Durvalumab, is a monoclonal antibody, a type of protein designed to recognize and attach to a protein called ‘programmed death-ligand 1’ (PD-L1), which is present on the surface of many cancer cells, produced in Chinese hamster Ovary (CHO) cells. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Expression of programmed cell death ligand-1 (PD-L1) protein is an adaptive immune response that helps tumours evade detection and elimination by the immune system. PD-L1 can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumour cells and 13 tumour-associated immune cells in the tumour microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation and cytokine production. Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Durvalumab does not induce antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation. |
| Original license holder | AstraZeneca |
| Marketing authorisation numbers | EU/1/18/1322/002 |
| Marketing authorisation holder | AstraZeneca AB SE-151 85 Södertälje Sweden |
| Name of the manufacturer of the biological active substance | AstraZeneca Pharmaceuticals LP Frederick Manufacturing Center (FMC) 633 Research Court Frederick, Maryland 21703 United States |
| Name and address of the manufacturer(s) responsible for batch release | MedImmune UK Ltd 6 Renaissance Way Liverpool, L24 9JW United Kingdom alternatively: MedImmune Pharma B.V. Lagelandseweg 78 6545CG Nijmegen, Netherlands |
| Max shelf life | 36 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Histidine Histidine hydrochloride monohydrate Trehalose dihydrate Polysorbate 80 |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
